Literature DB >> 16681591

Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in human malignant melanoma and their relation to angiogenesis.

Y-T Tu1, J Tao, Y-Q Liu, Y Li, C-Z Huang, X-B Zhang, Y Lin.   

Abstract

BACKGROUND: Angiogenesis is the major and key factor for growth and invasion of tumours, including malignant melanoma (MM), but the factors that contribute to tumour angiogenesis are still unclear.
OBJECTIVE: To study expression of endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) in human MM and their relation to angiogenesis. To investigate the correlation between eNOS and VEGF and the role of nitric oxide (NO) generated by eNOS in the process of mediating angiogenesis by VEGF.
METHODS: Tissue sections from 31 patients with MM were examined using immunohistochemistry and morphological quantitative analysis for protein expression of eNOS and VEGF. Microvessel density (MVD) was counted in endothelial cells in immunostained by anti-FVIII:RAg antibody.
RESULTS: Positive eNOS and VEGF immunostaining were observed in 77.4% and 83.9% of MM lesions, respectively, whereas pigmented naevi never expressed eNOS and VEGF. A positive correlation between eNOS and VEGF in MM was observed. Expression of eNOS and VEGF was positively correlated with MVD expression in MM, and MVD expression in MM was stronger than in pigmented naevi. Expression of eNOS and VEGF was not correlated with lymph node metastasis. CONCLUSIONS. On the basis of the current data showing that malignant melanocytic tumours displayed strong VEGF and eNOS expression, whereas benign melanocytic proliferations showed no immunoreactivity for VEGF and eNOS, such expression may be used as a discriminating factor to distinguish malignant melanoma from pigmented naevi. Expression of eNOS and VEGF may contribute to angiogenesis of MM, eNOS probably plays an important role in mediating VEGF-induced angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16681591     DOI: 10.1111/j.1365-2230.2006.02123.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  11 in total

Review 1.  Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target.

Authors:  Elizabeth A Grimm; Andrew G Sikora; Suhendan Ekmekcioglu
Journal:  Clin Cancer Res       Date:  2013-07-18       Impact factor: 12.531

2.  Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin.

Authors:  Ahmad A Tarhini; Paul Frankel; Kim A Margolin; Scott Christensen; Christopher Ruel; Janice Shipe-Spotloe; David R Gandara; Alice Chen; John M Kirkwood
Journal:  Clin Cancer Res       Date:  2011-08-31       Impact factor: 12.531

Review 3.  Immunology Comes Full Circle in Melanoma While Specific Immunity Is Unleashed to Eliminate Metastatic Disease, Inflammatory Products of Innate Immunity Promote Resistance.

Authors:  Elizabeth A Grimm
Journal:  Crit Rev Oncog       Date:  2016

4.  Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activity.

Authors:  Clara Curiel-Lewandrowski; Susan M Swetter; Janine G Einspahr; Chiu-Hsieh Hsu; Ray Nagle; Paul Sagerman; Joseph Tangrea; Howard Parnes; David S Alberts; Hsiao-Hui Chow
Journal:  Cancer       Date:  2012-05-17       Impact factor: 6.860

5.  Lack of correlation between microvascular density and pathological features and outcomes in sinonasal and oral mucosal melanomas.

Authors:  Elizabeth H Kerr; Dezhi Wang; James S Lewis; Nasser Said-Al-Naief; Omar Hameed
Journal:  Head Neck Pathol       Date:  2011-03-19

6.  β3-adrenergic receptor activity modulates melanoma cell proliferation and survival through nitric oxide signaling.

Authors:  Massimo Dal Monte; Irene Fornaciari; Grazie Paola Nicchia; Maria Svelto; Giovanni Casini; Paola Bagnoli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-03-06       Impact factor: 3.000

7.  Targeting hypoxia-inducible factor-1alpha with Tf-PEI-shRNA complex via transferrin receptor-mediated endocytosis inhibits melanoma growth.

Authors:  Yeqiang Liu; Juan Tao; Yan Li; Jing Yang; Yan Yu; Min Wang; Xiaoyuan Xu; Changzheng Huang; Wei Huang; Jing Dong; Li Li; Jing Liu; Guanxin Shen; Yating Tu
Journal:  Mol Ther       Date:  2008-12-09       Impact factor: 11.454

Review 8.  Neuroendocrine Factors in Melanoma Pathogenesis.

Authors:  Cristian Scheau; Carmen Draghici; Mihaela Adriana Ilie; Mihai Lupu; Iulia Solomon; Mircea Tampa; Simona Roxana Georgescu; Ana Caruntu; Carolina Constantin; Monica Neagu; Constantin Caruntu
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639

9.  Oxidative and nitrosative stress in the metastatic microenvironment.

Authors:  Angel L Ortega; Salvador Mena; José M Estrela
Journal:  Cancers (Basel)       Date:  2010-03-26       Impact factor: 6.639

10.  Inhibition of endothelial nitric oxide synthase in cholangiocarcinoma cell lines - a new strategy for therapy.

Authors:  Manida Suksawat; Anchalee Techasen; Nisana Namwat; Thianrut Boonsong; Attapol Titapun; Piti Ungarreevittaya; Puangrat Yongvanit; Watcharin Loilome
Journal:  FEBS Open Bio       Date:  2018-03-02       Impact factor: 2.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.